Fragment-based lead discovery using X-ray crystallography

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 403-413

  Hartshorn, Michael J ^a   Murray, Christopher W ^a   Cleasby, Anne ^a   Frederickson, Martyn ^a   Tickle, Ian J ^a   Jhoti, Harren ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; ESTERASE INHIBITOR; LEAD; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RIBONUCLEASE A; THROMBIN; THROMBIN INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; LIPOPHILICITY; METHODOLOGY; MOLECULAR INTERACTION; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY;

CDC2-CDC28 KINASES; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTEINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RIBONUCLEASE, PANCREATIC; THROMBIN;

EID: 12344318177     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0495778     Document Type: Article

References (63)

1. Campbell, S. F. Science, art and drug discovery: a personal perpsective. Clin. Sci. 2000, 99, 255-260.
2. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
3. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The Design of Leadlike Combinatorial Libraries. Angew. Chem., Int. Ed. 1999, 38, 3743-3748.
4. Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; Schoot, B.; Delettre, G.; Marquette, J. P.; Broto, P.; Jean-Baptiste, V.; Eichet, P.; Sarubbi, E.; Mandine, E. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.
5. Carr, R. and Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discovery Today 2002, 7, 522-527.
6. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand discovery. Proc. Natl. Acad. Sci. U. S. A 2000, 97, 9367-9372.
7. Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 2000, 18, 1105-1108.
8. Sanders, W. J.; Nienaber, V. L.; Lerner, C. G.; McCall, J. O.; Merrick, S. M.; Swanson, S. J.; Harlan, J. E.; Stoll, V. S.; Stamper, G. F.; Betz, S. F.; Condroski, K. R.; Meadows, R. P.; Severin, J. M.; Walter, K. A.; Magdalinos, P.; Jakob, C. G.; Wagner, R.; Beutel, B. A. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J. Med. Chem. 2004, 47, 1709-1718.
9. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, G. M., Jr.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. J. Am. Chem. Soc. 2004, 119, 5818-5827.
10. Boehm, H. J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller, N.; Mueller, F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem. 2000, 43, 2664-2674.
11. Lange, G.; Lesuisse, D.; Deprez, P.; Schoot, B.; Loenze, P.; Benard, D.; Marquette, J. P.; Broto, P.; Sarubbi, E.; Mandine, E. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J. Med. Chem. 2003, 46, 5184-5195.
12. van Dongen, M.; Weigelt, J.; Uppenberg, J.; Schultz, J.; Wikstrom, M. Structure-based screening and design in drug discovery. Drug Discovery Today 2002, 7, 471-478.
13. van Dongen, M. J.; Uppenberg, J.; Svensson, S.; Lundback, T.; Akerud, T.; Wikstrom, M.; Schultz, J. Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. J Am. Chem. Soc. 2002, 124, 11874-11880.
14. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem. Biol. 1999, 6, 755-769.
15. Maly, D. J.; Choong, I. C.; Ellman, J. A. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2419-2424.
16. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
17. Blundell, T.L.; Abell, C.; Cleasby, A.; Hartshorn, M.J.; Tickle, I.J.; Parasini, E.; Jhoti, H. High-throughput X-ray crystallography for drug discovery. In Drug design: special publication; Flower, D. R., Ed.; Royal Society of Chemistry: Cambridge, UK, 2002; pp 53-59.
18. Muchmore, S. W.; Olson, J.; Jones, R.; Pan, J.; Blum, M.; Greer, J.; Merrick, S. M.; Magdalinos, P.; Nienaber, V. L. Automated crystal mounting and data collection for protein crystallography. Struct. Fold. Des. 2000, 8, R243-R246.
19. Sharff, A. J. High throughput crystallography on an in-house source, using ACTOR. Rigaku J. 2004, 20, 10.
20. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
21. Bemis, G. W. and Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
22. Bemis, G. W. and Murcko, M. A. Properties of known drugs. 2. Side chains. J. Med. Chem. 1999, 42, 5095-5099.
23. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
24. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
25. Verdonk, M. L.; Cole, J. C.; Hartshorn, M.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
26. Watson, P.; Verdonk, M. L.; Hartshorn, M. J. A web-based platform for virtual screening. J. Mol. Graph. Model. 2003, 22, 71-82.
27. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A 'rule of three' for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877.
28. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic Generation of 3D-Atomic Coordinates for Organic Molecules. Tetrahedron Comput. Methodol. 2004, 3, 537-547.
29. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead, D. R.; Eldridge, M. D. Flexible docking using Tabu search and an empirical estimate of binding affinity. Proteins 1998, 33, 367-881.
30. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
31. Gohlke, H.; Hendlich, M.; Hebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
32. Hartshorn, M. J. AstexViewer: a visualisation aid for structure-based drug design. J. Comput.-Aided Mol. Des. 2002, 16, 871-881.
33. Gum, R. J.; McLaughlin, M. M.; Kumar, S.; Wang, Z.; Bower, M. J.; Lee, J. C.; Adams, J. L.; Livi, G. P.; Goldsmith, E. J.; Young, P. R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 1998, 273, 15605-15610.
34. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S. H. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 2001, 44, 524-530.
35. Groves, M. R.; Yao, Z. J.; Roller, P. P.; Burke, T. R., Jr.; Barford, D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 1998, 37, 17773-17783.
36. Jia, Z.; Ye, Q.; Dinaut, A. N.; Wang, Q.; Waddleton, D.; Fayette, P.; Ramachandran, C.; Kennedy, B.; Hum, G.; Taylor, S. D. Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics. J. Med. Chem. 2001, 44, 4584-4594.
37. Wang, Z.; Harkins, P. C.; Ulevitch, R. J.; Han, J.; Cobb, M. H.; Goldsmith, E. J. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc. Natl. Acad. Sci. U. S. A 1987, 94, 2327-2332.
38. Schulze-Gahmen, U.; De Bondt, H. L.; Kim, S. H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 1996, 39, 4540-4546.
39. Jhoti, H.; Cleasby, A.; Reid, S.; Thomas, P. J.; Weir, M.; Wonacott, A. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template. Biochemistry 1999, 38, 7969-7977.
40. Andersen, H. S.; Iversen, L. F.; Jeppesen, C. B.; Branner, S.; Norris, K.; Rasmussen, H. B.; Moller, K. B.; Moller, N. P. 2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 2000, 275, 7101-7108.
41. Leonidas, D. D.; Shapiro, R.; Irons, L. I.; Russo, N.; Acharya, K. R. Crystal structures of ribonuclease A complexes with 5′-diphosphoadenosine 3′-phosphate and 5′-diphosphoadenosine 2′-phosphate at 1.7 A resolution. Biochemistry 1997, 36, 5578-5588.
42. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr. D. 1999, 55 (Pt. 10), 1718-1725.
43. Leslie, A. G. W.; Brick, P.; Wonacott, A. MOSFLM. Daresbury Lab. Inf. Quart. Protein Crystallogr. 2004, 18, 33-39.
44. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 2004, A50, 157-163.
45. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D. 1998, 54 (Pt. 5), 905-921.
46. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood Method. Acta Crystallogr. D. 2004, D53, 240-255.
47. Salituro, F. G.; Germann, U. A.; Wilson, K. P.; Bemis, G. W.; Fox, T.; Su, M. S. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Curr. Med. Chem. 1999, 6, 807-823.
48. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C. A.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A. E.; Jhoti, H. Identification of Novel p38α MAP Kinase Inhibitors using Fragment-Based Lead Generation. J. Med. Chem. 2005, 48, 414-426.
49. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38alpha MAP kinase quinazolinone and pyridolpyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10, 764-769.
50. Fischer, P. M. and Lane, D. P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 2000, 7, 1213-1245.
51. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
52. Sausville, E. A.; Zaharevitz, D.; Gussio, R.; Meijer, L.; Louarn-Leost, M.; Kunick, C.; Schultz, R.; Lahusen, T.; Headlee, D.; Stinson, S.; Arbuck, S. G.; Senderowicz, A. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 1999, 82, 285-292.
53. Pierce, A. C.; Sandretto, K. L.; Bemis, G. W. Kinase inhibitors and the case for CH⋯O hydrogen bonds in protein-ligand binding. Proteins 2002, 49, 567-576.
54. Fenton, J. W.; Ofosu, F. A.; Moon, D. G.; Maraganore, J. M. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagul. Fibrinolysis 1991, 2, 69-75.
55. Adler, M.; Kochanny, M. J.; Ye, B.; Rumennik, G.; Light, D. R.; Biancalana, S.; Whitlow, M. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry 2002, 41, 15514-15523.
56. Sanderson, P. E.; Cutrona, K. J.; Dyer, D. L.; Krueger, J. A.; Kuo, L. C.; Lewis, S. D.; Lucas, B. J.; Yan, Y. Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg. Med. Chem. Lett. 2003, 13, 161-164.
57. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J. Med. Chem. 1998, 41, 3210-3219.
58. Vitagliano, L.; Merlino, A.; Zagari, A.; Mazzarella, L. Productive and nonproductive binding to ribonuclease A: X-ray structure of two complexes with uridylyl(2′,5′)guanosine. Protein Sci. 2000, 9, 1217-1225.
59. Fischer, E. H.; Charbonneau, H.; Tonks, N. K. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science 1991, 253, 401-406.
60. Andersen, H. S.; Iversen, L. F.; Jeppesen, C. B.; Branner, S.; Norris, K.; Rasmussen, H. B.; Moller, K. B.; Moller, N. P. 2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J. Biol. Chem. 2000, 275, 7101-7108.
61. Finkelstein, A. V. and Janin, J. The price of lost freedom: entropy of bimolecular complex formation. Protein Eng. 1989, 3, 1-3.
62. Murray, C. W. and Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comput.-Aided Mol. Des. 2002, 16, 741-753.
63. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.